Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER Office Of Biotech Products To Oversee Biologics Quality After Transition

Executive Summary

Center for Drug Evaluation & Research Office of New Drug Chemistry Director Yuan-yuan Chiu, PhD, will serve as acting director of FDA's Office of Biotech Products when the office is officially established in October

You may also be interested in...



FDA Biotech Products Office Acting Director Is CBER Veteran Webber

FDA Office of Biotechnology Products Acting Director Keith Webber, PhD, will bring a CBER perspective to the office's quality review functions

FDA Biotech Products Office Acting Director Is CBER Veteran Webber

FDA Office of Biotechnology Products Acting Director Keith Webber, PhD, will bring a CBER perspective to the office's quality review functions

CBER/CDER Consolidation: 20 Staff Vacancies, Two ODE VI Clinical Divisions

FDA is actively recruiting to replace 20 staffers who have left the Center for Biologics Evaluation & Research since plans to consolidate with CDER were announced a year ago

Related Content

UsernamePublicRestriction

Register

PS041838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel